Abstract
Pts with nmCRPC are at high risk of developing metastases if they have a prostate-specific antigen (PSA) doubling time (PSADT) of ≤10 months (mo) or Gleason score (GS) ≥8. Combining androgen deprivation therapy (ADT) with novel hormone therapies (NHTs; apalutamide/darolutamide/enzalutamide) prolongs metastasis-free survival (MFS) and overall survival (OS) in nmCRPC, but data on use of these therapies in real-world settings are minimal. We assessed the real-world use of NHTs in men with high-risk nmCRPC in the United States.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
